OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
+$204M |
| 2 |
Perrigo
PRGO
|
+$111M |
| 3 |
AbbVie
ABBV
|
+$99.2M |
| 4 |
CELG
Celgene Corp
CELG
|
+$71.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$70.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$169M |
| 2 |
Elevance Health
ELV
|
+$69M |
| 3 |
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
|
+$56.2M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$53.1M |
| 5 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$52.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.54% |
| 2 | Miscellaneous | 13.17% |
| 3 | Financials | 1.18% |
| 4 | Technology | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$213B
| $375M | 5.51% |
4,992,600
+214,800
| +4% | +$15M |
2013 Q2
2 quarters
|
|
2
Biogen
BIIB
$37.3B
| $306M | 4.5% |
1,095,100
+68,700
| +7% | +$17.8M |
2013 Q2
2 quarters
|
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $297M | 4.36% |
3,514,200
+900,200
| +34% | +$71.2M |
2013 Q2
2 quarters
|
|
4
Bristol-Myers Squibb
BMY
$128B
| $290M | 4.27% |
5,465,000
+261,000
| +5% | +$13.3M |
2013 Q2
2 quarters
|
|
5
Amgen
AMGN
$252B
| $287M | 4.22% |
2,515,300
-114,300
| -4% | -$13M |
2013 Q2
2 quarters
|
|
|
RLYP
6
DELISTED
RELYPSA INC COM
RLYP
| $249M | 3.65% |
+9,941,549
| New | +$204M |
2013 Q4
0 quarters
|
|
7
Incyte
INCY
$24.3B
| $206M | 3.03% |
4,069,000
-404,000
| -9% | -$17.6M |
2013 Q2
2 quarters
|
|
8
Regeneron Pharmaceuticals
REGN
$94.6B
| $203M | 2.99% |
738,800
+225,700
| +44% | +$64.9M |
2013 Q2
2 quarters
|
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $199M | 2.93% |
6,247,000
+1,678,000
| +37% | +$50.7M |
2013 Q2
2 quarters
|
|
|
10
AbbVie
ABBV
$520B
| $199M | 2.92% |
3,760,900
+2,018,900
| +116% | +$99.2M |
2013 Q2
2 quarters
|
|
11
Viatris
VTRS
$21.9B
| $183M | 2.69% |
4,214,500
-834,500
| -17% | -$34.3M |
2013 Q2
2 quarters
|
|
12
HCA Healthcare
HCA
$103B
| $179M | 2.64% |
3,758,000
+705,000
| +23% | +$32.6M |
2013 Q2
2 quarters
|
|
13
Illumina
ILMN
$35.7B
| $177M | 2.6% |
1,641,510
+3,084
| +0.2% | +$282K |
2013 Q2
2 quarters
|
|
14
Agilent Technologies
A
$49.4B
| $173M | 2.54% |
4,218,605
+1,078,697
| +34% | +$41M |
2013 Q2
2 quarters
|
|
15
Thermo Fisher Scientific
TMO
$256B
| $171M | 2.51% |
1,534,200
-11,800
| -0.8% | -$1.17M |
2013 Q2
2 quarters
|
|
|
16
Merck
MRK
$369B
| $127M | 1.87% |
2,669,256
-3,698,392
| -58% | -$169M |
2013 Q2
2 quarters
|
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $120M | 1.76% |
713,000
+237,900
| +50% | +$37.2M |
2013 Q2
2 quarters
|
|
|
18
Perrigo
PRGO
$2.17B
| $119M | 1.74% |
+773,000
| New | +$111M |
2013 Q4
0 quarters
|
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $118M | 1.74% |
1,734,934
-416,673
| -19% | -$24.1M |
2013 Q2
2 quarters
|
|
|
ITMN
20
DELISTED
INTERMUNE INC
ITMN
| $113M | 1.67% |
7,697,000
+4,809,400
| +167% | +$66.5M |
2013 Q2
2 quarters
|
|
21
Pfizer
PFE
$174B
| $109M | 1.6% |
3,744,862
-482,100
| -11% | -$14M |
2013 Q2
2 quarters
|
|
22
Insulet
PODD
$10.5B
| $107M | 1.57% |
2,888,500
+36,000
| +1% | +$1.33M |
2013 Q2
2 quarters
|
|
|
IPXL
23
DELISTED
Impax Laboratories, Inc.
IPXL
| $107M | 1.57% |
4,237,600
+951,900
| +29% | +$21.2M |
2013 Q2
2 quarters
|
|
|
SHPG
24
DELISTED
Shire pic
SHPG
| $102M | 1.5% |
724,000
+33,100
| +5% | +$4.35M |
2013 Q3
1 quarter
|
|
25
BioMarin Pharmaceuticals
BMRN
$11.3B
| $99.5M | 1.46% |
1,414,100
-167,600
| -11% | -$11.4M |
2013 Q2
2 quarters
|
|
Similar funds
OrbiMed's Q4 2013 Portfolio in Review
As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
OrbiMed deployed $636M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Merck, an estimated $169M trimmed.
- OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
- OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
- OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
- OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
- OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
- OrbiMed opened 24 new positions and closed 34 in Q4 2013.
- OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.
Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.